KNTE

Analyst Sentiment

Wall St. Consensus
Hold
6 analysts·Limited coverage
58
Score
2 Buy (33%)4 Hold (67%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
233%
Hold
467%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$30.00
+1032.1%
Consensus
$30.00
+1032.1%
Bull
$30.00
+1032.1%
12-Month Target Range6 analysts
$30.00$30.00$30.00
Current $2.65Consensus
Current Price
$2.65
Upside to Consensus
$27.35

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
FY2028
Rev+221.29%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$61M$197M
Low$61M$197M
High$61M$197M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-45M$-52M$-18M
Low$-53M$-52M$-18M
High$-37M$-52M$-18M
EPS Avg$-0.97$-1.11$-0.38
Low$-1.15$-1.11$-0.38
High$-0.79$-1.11$-0.38
Analysts (Rev / EPS) / 21 / 11 / 1

Earnings Surprises

Recent Analyst Actions

May 18, 2022Piper Sandler
Kinnate Biopharma price target lowered to $30 from $52 at Piper Sandler
Target:$30.00
+201.2%from $9.96
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.